Saturday 24 October 2026 · Edition of the day

Current editionPast editions →

The Skeptic's Daily

The day's biggest stories, taken apart. For each one: what is actually established, what is only asserted, the questions worth asking — and a plausibility score for the central claim, given everything currently known.

Stories
1
Average plausibility
83%
How to read the score
It rates how well the core claim is evidenced — not how important the story is, nor whether it is good or bad news.
RegionAllGlobalAfricaNorth AmericaSouth AmericaAsia-PacificEuropeMiddle East
TopicAllPoliticsConflict & SecurityBusinessScienceHealth
01HealthGlobal

Personalized cancer vaccine trial reports reduced recurrence risk

Two outlets describe favorable trial results, but the excerpts omit the effect size and study methods.

The BBC reports that a personalized cancer vaccine reduced the risk of disease returning in a major trial. The Guardian describes a bespoke mRNA vaccine trial showing a significant reduction in the risk of melanoma recurrence or death.

What holds up

  • ✓Both outlets report favorable clinical trial findings for a personalized cancer vaccine.
  • ✓Both accounts describe reduced recurrence risk, with The Guardian specifying melanoma and an outcome including death.

What doesn't yet

  • ?Neither excerpt supplies trial size, comparator, follow-up duration, effect size or safety findings.
  • ?Descriptions of a turning point or foundational shift reflect researchers' interpretations, not proof of broad clinical benefit.

Ask before you share

  • →What were the absolute risk reduction, comparator and follow-up period?
  • →Which patients were studied, and what adverse effects occurred?

Sources & original reporting

  1. [1]BBC News · Published 23 Oct 2026 · bbc.co.uk
  2. [2]The Guardian · Published 23 Oct 2026 · theguardian.com